(Q37772444)

22 August 2017

1 reference

title

BRAF, a target in melanoma: implications for solid tumor drug development (English)

1 reference

22 August 2017

Grant McArthur

2

0 references

Keith Flaherty

series ordinal

1

object named as

Keith T Flaherty

1 reference

PubMed ID

20629085

22 August 2017

language of work or name

English

0 references

publication date

1 November 2010

1 reference

22 August 2017

1 reference

22 August 2017

116

1 reference

22 August 2017

4902-4913

1 reference

22 August 2017

21

1 reference

BRAF mutations in aberrant crypt foci and hyperplastic polyposis

22 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Guilty as charged: B-RAF is a human oncogene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Mutations of the BRAF gene in benign and malignant melanocytic lesions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

BRAF Mutation in Papillary Thyroid Carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

BRAF and KRAS mutations in prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

BRAF and K-ras gene mutations in human pancreatic cancers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Mutations of the BRAF gene in squamous cell carcinoma of the head and neck.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Improving melanoma classification by integrating genetic and morphologic features

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Correlation Between Genetic Alterations and Microscopic Features, Clinical Manifestations, and Prognostic Characteristics of Thyroid Papillary Carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Distinct sets of genetic alterations in melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

B-RAF is a therapeutic target in melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

V599EB-RAF is an oncogene in melanocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Oncogenic Braf induces melanocyte senescence and melanoma in mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

High frequency of BRAF mutations in nevi

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

BRAFE600-associated senescence-like cell cycle arrest of human naevi

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

A novel transforming gene in a human malignant melanoma cell line

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

N-ras mutations in human cutaneous melanoma from sun-exposed body sites.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

BRAF alterations are associated with complex mutational profiles in malignant melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

The prevalence of PIK3CA mutations in gastric and colon cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

BRAF mutations in papillary carcinomas of the thyroid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

BRAF mutation predicts sensitivity to MEK inhibition

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25261

7 January 2021

Identifiers

DOI

10.1002/CNCR.25261

1 reference

22 August 2017

1 reference

PubMed ID

20629085